Italian biopharmaceutical company Kedrion warns: Conflicts may affect drug supply to Iran.

Italian biopharmaceutical company Kedrion has warned that if conflicts with Iran result in disruptions to the supply chain, the company may struggle to ensure timely delivery of crucial plasma-derived medicines to patients in Iran. The company's CEO Ugo Di Francesco stated that the performance report released by the company this week confirms strong growth over the past few years, but he is concerned that rising fuel prices will impact logistical costs.